Adaptive Bridging Radiation Therapy for the Treatment of Patients Planning to Undergo CAR T-cell Therapy for Recurrent or Refractory B-cell Lymphoma
This clinical trial evaluates the safety, effectiveness, and feasibility of delivering adaptive bridging radiation therapy to patients who are planning to receive chimeric antigen receptor T-cell (CAR T) therapy for B-cell lymphoma that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory). The time frame between when a patient is determined to be eligible for CAR T therapy and when they actually receive the therapy can be up to 2-3 months. During this time frame, the patients' performance status may decline and/or their disease may get worse. Bridging therapy is treatment given between the collection of a patient's T-cells and the CAR T infusion as a way to prevent disease progression and allow patients to safely wait until their CAR T-cells are ready to be infused. Adaptive radiation therapy gives treatment providers the ability to modify the radiation plan (location and dosage) at each treatment cycle based on real-time imaging to maximize disease control and reduce damage to healthy tissues. Adaptive bridging radiation therapy may be a safe way to control disease in patients who are waiting to undergo CAR T therapy for recurrent or refractory B-cell lymphoma.